Catherine Jennings: Marking Today as an Important Step Forward for Patients With PE
Catherine Jennings, President, Peripheral Vascular at Boston, shared a post on LinkedIn:
“Today marks an important step forward for patients with pulmonary embolism (PE) and for the future of PE care.
This morning at ACC 26, we presented positive results from the HI-PEITHO randomized clinical trial, demonstratinge that the EKOS Endovascular System plus anticoagulation was superior to the current standard of care, anticoagulation alone, for the treatment of acute intermediate-risk PE.
The study, which was also simultaneously published in The New England Journal of Medicine, met its primary endpoint of PE-related mortality, non-fatal hemodynamic cardiorespiratory decompensation or collapse and non-fatal symptomatic recurrence of PE within seven days (4.0% vs. 10.3%; p=0.005), representing a 61% reduction in primary endpoint events.
PE is the third leading cause of cardiovascular mortality, impacting nearly one million patients annually in the U.S. and Europe. Despite that burden, relatively few patients today receive interventional therapy.
As the largest global randomized controlled trial comparing an interventional therapy to anticoagulation alone for acute PE using clinically meaningful endpoints, the HI-PEITHO study provides important clinical evidence to help inform treatment decisions and potentially influence future care pathways.
We are proud of what the HI-PEITHO study represents for patients, physicians and the future of PE care.”
Title: Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism
Authors: Kenneth Rosenfield, Frederikus A. Klok, Gregory Piazza, Andrew S. P. Sharp, Fionnuala Ní Áinle, Michael R. Jaff, Stefano Barco, Samuel Z. Goldhaber, Nils Kucher, Irene M. Lang, Irene Schmidtmann, Keith M. Sterling, Aleksander Araszkiewicz, Vishal Arora, Rafael Cires-Drouet, John Coghlan, Lukas Hobohm, Wulf D. Ito, Kurt Jacobson, Christoph Kaiser, Grzegorz Kopec, Kristin Marx, Samuel McElwee, Nicolas Meneveau, Peter Monteleone, Jose M. Montero-Cabezas, Christoph B. Olivier, John Park, Marek Roik, Rahul Sakhuja, Andi Tego, Markus Theurl, Gautam Visveswaran, Jan Albert Vos, Michael N. Young, Federico M. Asch, Stavros V. Konstantinides
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 2, 2026, 17:11Arun V. J: Our Clinical Audit on Transfusion Safety Has Been Selected at CAHOCON 2026
-
Apr 2, 2026, 17:10Maxime Dely: Better Collection, Better Blood – The Quality Starts Now
-
Apr 2, 2026, 17:09Arun Danewa: Saving a Bone Marrow Patient from Hidden Enemy – TA-TMA
-
Apr 2, 2026, 17:07Cathy Harrison: The WFH Nurses Committee are Looking for New Members
-
Apr 2, 2026, 16:30Sam K. Saha: The Hardest Cases Are the Ones You Can’t Save
-
Apr 2, 2026, 16:20Veronica Sanchez: Know Stroke Signs and Act Fast
-
Apr 2, 2026, 16:08Ney Carter Borges: Early Surgery vs Conservative Care in Asymptomatic Very Severe Aortic Stenosis
-
Apr 2, 2026, 15:52Gevorg Yaghjyan: How Yale is Redefining Bladder Cancer Treatment Through Strategy Focused Trials
-
Apr 2, 2026, 15:10Webinar on the Role of Omega-3 Fatty Acids in Cardiovascular Health – EAS